Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
128.99
-0.23 (-0.18%)
Streaming Delayed Price
Updated: 11:36 AM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
82
83
Next >
Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer
November 01, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unresectable or
Via
Benzinga
Exposures
Product Safety
A Look Into Merck & Co Inc's Price Over Earnings
November 01, 2023
Via
Benzinga
Merck to Participate in the UBS BioPharma Conference
November 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
November 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Check Out What Whales Are Doing With MRK
October 23, 2023
Via
Benzinga
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
November 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
October 31, 2023
In due time, its new partnership with Daiichi Sankyo could be massive.
Via
The Motley Fool
Jim Cramer Says Hold Onto This Tech Stock, But 'You're Not Going To Make A Lot Of Money In It Right Now, Because That Was A Really Terrible Last Quarter'
October 31, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Corning Incorporated (NYSE: GLW) reported a disappointing quarter.
Via
Benzinga
2 No-Brainer AI Stocks to Buy and One to Run Away From
October 31, 2023
Artificial intelligence is altering the business landscape and opening up unique AI stocks to buy as well as ones to avoid.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
October 28, 2023
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its...
Via
Talk Markets
3 Deeply Undervalued Growth Stocks
October 27, 2023
As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks.
Via
InvestorPlace
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
October 27, 2023
Microsoft, Google, Amazon and Meta led big earnings.
Via
Investor's Business Daily
Merck (MRK) Q3 2023 Earnings Call Transcript
October 26, 2023
MRK earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Pharma Giant Merck's Shares Are Shooting Higher Today
October 26, 2023
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion,
Via
Benzinga
Here's How Merck's Heavyweight Cancer Drug Helped Deliver Another Beat-And-Raise Quarter
October 26, 2023
The company lowered its earnings outlook, however, due to a new development deal with Daiichi Sankyo.
Via
Investor's Business Daily
Nasdaq Futures Plunge As Meta Warns Of Q4 Softness: GDP Data, Amazon Earnings On Investors' Radar Amid Market Mayhem
October 26, 2023
Stock futures are plunging after the mega-cap tech names haven't turned in the strong results that the markets had factored in.
Via
Benzinga
Merck Announces Third-Quarter 2023 Financial Results
October 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
October 23, 2023
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
October 22, 2023
The companies studied a combination of Keytruda and Padcev in bladder cancer patients.
Via
Investor's Business Daily
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
October 23, 2023
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
October 22, 2023
From
Merck & Co., Inc.
Via
Business Wire
3 Safe Dividend Stocks to Beat Inflation
October 21, 2023
Higher prices make things tougher for consumers and companies alike. Some corporations, however, are capable of pushing through this headwind.
Via
The Motley Fool
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
October 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
October 20, 2023
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon.
Via
Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.